Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT).

John F. DiPersio,Brenda Cooper,Hyung C. Suh,Divya Koura,Léa Bernard,Nirali N. Shah,Roland B. Walter,Miguel-Angel Perales,Markus Y. Mapara,Roni Tamari,Michael Loken,Kyle Breitschwerdt,Sritama Nath,Glen D Raffel,Guenther Koehne

doi:10.1016/j.jtct.2023.12.311

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT).

John F. DiPersio, Brenda Cooper + Show 13 more

https://doi.org/10.1016/j.jtct.2023.12.311

Copy DOI

Journal: Transplantation and Cellular Therapy

Publication Date: Feb 1, 2024

#High-Risk Acute Myeloid Leukemia #Gemtuzumab Ozogamicin + Show 7 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT).

Full Text